Borderline SCRHD is marked by elevated IL-6 levels that last for at least 2 years, indicating a sustained proinflammatory state from the earliest detectable stage of the disease. These findings identify interleukin-6 as a potential early biomarker and therapeutic target to prevent the progression of SCRHD.
Branco et al. (Tue,) studied this question.